<DOC>
	<DOCNO>NCT02433314</DOCNO>
	<brief_summary>This open-label , expanded access protocol , design offer treatment SAGE-547 subject SRSE , evaluate efficacy safety SAGE-547 administer continuous intravenous infusion subject</brief_summary>
	<brief_title>An Open Label , Expanded Access Protocol With SAGE-547 Super-Refractory Status Epilepticus</brief_title>
	<detailed_description />
	<mesh_term>Status Epilepticus</mesh_term>
	<criteria>Subjects six ( 6 ) month age old Subjects : Failed respond administration least one firstline agent ( e.g. , benzodiazepine emergent initial AED treatment ) , accord institution 's standard care , ; Failed respond least one secondline agent ( e.g. , phenytoin , fosphenytoin , valproate , phenobarbital , levetiracetam urgent control AEDs ) , accord institution 's standard care , ; Not previously administer thirdline agent admit intensive care unit intent administer least one thirdline agent least 24 hour ; previously fail zero , one wean attempt thirdline agent continuous intravenous infusion one thirdline agent EEG burst seizure suppression pattern ; previously fail one wean attempt thirdline agent either least one continuous infusion thirdline agent one continuous infusion thirdline agent EEG burst seizure suppression pattern . Subjects SRSE due anoxic/hypoxic encephalopathy highly malignant/ malignant EEG feature Children ( subject age less 18 year ) encephalopathy due underlie progressive neurological disorder Subjects follow : 1. GFR low enough warrant dialysis whatever reason , dialysis plan noncontinuous dialysis plan ; 2. severe cardiogenic vasodilatory shock require two pressor related thirdline agent use ; 3. fulminant hepatic failure ; 4. reasonable expectation recovery lifeexpectancy le 30 day . Subjects administer three thirdline agent concomitantly qualify wean complete per protocol</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>